CAJ | 학술논문

目的：通过分析恶性肿瘤患者化疗后合并医院感染的临床资料，探讨此类患者医院感染的特点及易感因素。方法：采用病例回顾对照方法，对2013年8月-2014年7月作者所在医院的恶性肿瘤患者化疗后发生医院感染的病例资料进行分析。结果：在7112例住院的恶性肿瘤化疗患者中发生医院感染病例934份，感染率为13.13%；其中肝、肺、胰腺恶性肿瘤患者的感染率较高；感染部位主要以呼吸系统感染为主，其次为消化系统，有364（38.97%）例病例，感染部位不明确；感染的病原菌主要以革兰氏阴性菌为主；不同性别对医院感染的发生率的影响，比较无统计学意义（P>0.05）；年龄>70岁，住院时间>14d，肿瘤临床分期在Ⅲ~Ⅳ期， ANC<1.5×109/L、低蛋白血症、化疗周期大于4、合并糖尿病或乙肝的患者更易发生医院感染，比较差异具有统计学意义（P<0.05）。结论：通过对恶性肿瘤患者化疗后发生医院感染的发病特点及相关因素进行分析，为临床预防与治疗恶性肿瘤患者医院感染提供依据。
목적：통과분석악성종류환자화료후합병의원감염적림상자료，탐토차류환자의원감염적특점급역감인소。방법：채용병례회고대조방법，대2013년8월-2014년7월작자소재의원적악성종류환자화료후발생의원감염적병례자료진행분석。결과：재7112례주원적악성종류화료환자중발생의원감염병례934빈，감염솔위13.13%；기중간、폐、이선악성종류환자적감염솔교고；감염부위주요이호흡계통감염위주，기차위소화계통，유364（38.97%）례병례，감염부위불명학；감염적병원균주요이혁란씨음성균위주；불동성별대의원감염적발생솔적영향，비교무통계학의의（P>0.05）；년령>70세，주원시간>14d，종류림상분기재Ⅲ~Ⅳ기， ANC<1.5×109/L、저단백혈증、화료주기대우4、합병당뇨병혹을간적환자경역발생의원감염，비교차이구유통계학의의（P<0.05）。결론：통과대악성종류환자화료후발생의원감염적발병특점급상관인소진행분석，위림상예방여치료악성종류환자의원감염제공의거。
Objective:To analyze the clinical data chemotherapy consolidation of hospital infection in cancer patients, and to explore the characteristics of nosocomial infection in these patients and predisposing factors. Methods: August 2013 - July 2014 where the author hospital clinical data Chemotherapy nosocomial infections in cancer patients were analyzed retrospectively. Results: In 7112 cases of cancer chemotherapy nosocomial infections occurred in 934 copies, the infection rate was 13.13%;where the liver, lung, pancreas cancer prevalence higher;site of infection mainly respiratory infections, followed by the digestive system, which has 364 (38.97%)cases, the site of infection is not clear;infection pathogens mainly Gram-negative bacteria dominated;different gender on the incidence of nosocomial infections affect, no significant difference (P>0.05);aged>70 years of age, length of stay>14d, clinical stage in Ⅲ~Ⅳ, ANC<1.5×109/L, hypoalbuminemia, the number of chemotherapy cycles greater than 4, or hepatitis B patients with diabetes are more likely to nosocomial infection compared with statistical significance(P<0.05). Conclusion:The combined hospital discharge for patients with cancer/chemotherapy infection characteristics and related factors analysis, to provide prevention and treatment of cancer clinical hospital discharge/infection after chemotherapy to provide evidence.